Stocks Health care ANVS
NYSE · Health careAnnovis Bio, Inc. (ANVS)
It posted a net loss of $49.5M. At June 30, 2026 it held $18.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Annovis Bio, Inc.
- Net worth
- Annovis Bio, Inc. has a market value (market cap) of $36M at the latest share price, and shareholders' equity of -$4.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0, with a net loss of $28.9M.
- Cash flow
- In fiscal 2025 operations used $25.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Annovis Bio, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Annovis Bio, Inc. does
Annovis Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker ANVS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$28.9M | -$1.40 | n/a |
| 2024 | $0 | -$24.6M | -$2.31 | n/a |
| 2023 | $0 | -$56.2M | -$6.23 | n/a |
| 2022 | $0 | -$25.3M | -$3.10 | n/a |
| 2021 | $0 | -$14.5M | -$1.90 | n/a |
| 2020 | $0 | -$5.5M | -$0.87 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Annovis Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 11, 2026Proxy statement DEF 14A
- August 25, 2026Preliminary proxy statement PRE 14A
- August 14, 2026
- August 14, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- July 10, 2026Other event 8-K
- June 17, 2026
- May 20, 2026
- May 15, 2026
Insider trades
What the people running Annovis Bio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 20, 2026 | Hoffman Michael BDirector | Bought | 2,562 | $4.5K |
| May 20, 2026 | Hoffman Michael BDirector | Bought | 18,849 | $33.9K |
| May 20, 2026 | Hoffman Michael BDirector | Bought | 54,933 | $104.4K |
| April 2, 2026 | Hoffman Michael BDirector | Bought | 713,800 | $1.5M |
| December 8, 2025 | Hoffman Michael BDirector | Bought | 30,000 | $130.2K |
| December 8, 2025 | Hoffman Michael BDirector | Bought | 15,000 | $63.6K |
| November 24, 2025 | Hoffman Michael BDirector | Bought | 1,489 | $6.1K |
| November 24, 2025 | Hoffman Michael BDirector | Bought | 9,200 | $35.4K |
Who owns ANVS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Highbridge Capital Management, LLC13G, passive | 6.1% | August 14, 2026 |
| Empery Asset Management, LP13G, passive with 1 related filers | 5.64% | July 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 61 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Empery Asset Management, LP | 2,401,476 | new |
| Marshall Wace, Llp | 1,842,339 | +654,840 |
| Vanguard Capital Management LLC | 1,647,322 | +774,941 |
| Tudor Investment Corp ET AL | 1,357,134 | new |
| Renaissance Technologies LLC | 1,002,200 | +654,600 |
| Two Sigma Investments, LP | 579,571 | -48,088 |
| Geode Capital Management, LLC | 283,817 | +36,304 |
| BlackRock, Inc. | 249,856 | +110,323 |
| Citadel Advisors LLC | 243,682 | new |
| Vanguard Fiduciary Trust Co | 177,530 | +45,488 |
| Susquehanna International Group, Llp | 146,804 | -71,532 |
| Quadrature Capital Ltd | 90,884 | new |
| State Street Corp | 77,735 | 0 |
| Northern Trust Corp | 68,070 | -73,660 |
| First National Trust Co | 60,000 | +20,000 |
| Sherry Group, Inc. | 57,270 | 0 |
| Headlands Technologies LLC | 48,071 | new |
| Wescott Financial Advisory Group, LLC | 41,607 | 0 |
| Bridgeway Capital Management, LLC | 37,677 | 0 |
| Wells Fargo & Company | 30,307 | +16,000 |
Insiders
3 insiders reported holding 4,590,612 shares in total, about $3.9M at the last price.
| Holder | Shares |
|---|---|
| Hoffman Michael BDirector | 3,364,883 |
| Maccecchini Maria-LuisaPresident & CEO, Director | 1,212,020 |
| Bruck ClaudineDirector | 13,709 |
Questions about ANVS
What does Annovis Bio, Inc. do?
Annovis Bio, Inc. is a company in the Health care sector, listed on NYSE as ANVS. Its shares trade on NYSE under the ticker ANVS.
What is Annovis Bio, Inc.'s net worth?
Annovis Bio, Inc. has a market value (market cap) of $36M at the latest share price, and shareholders' equity of -$4.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Annovis Bio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $49.5M.
When did Annovis Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the proxy statement from September 11, 2026.
When is Annovis Bio, Inc.'s next earnings report?
Annovis Bio, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ANVS with
Follow ANVS
Get an email when Annovis Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Annovis Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.